What changed in this filing

/stocks — the workspaceLOADING

Item 9A. Controls and Procedures

2025-06-27 compared with 2024-06-24 · 571 added, 301 removed, 146 unchanged (86% of the section changed)

Controls and Procedures

(a) Evaluation of disclosure controls and procedures

Our Management maintains disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to Management, including our Chief Executive Officer and Principal Financial Officer (our principal executive officer and principal financial officer, respectively), as appropriate, to allow for timely decisions regarding required disclosure.

Our Management, including the Chief Executive Officer and Principal Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report.

Based on this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective to ensure that the information required to be disclosed in the reports filed or submitted by us under the Exchange Act was recorded, processed, summarized and reported within the requisite time periods specified in SEC rules and forms and that such information was accumulated and communicated to our Management, including our Chief Executive Officer and Principal Financial Officer, as appropriate to allow for timely decisions regarding required disclosure.

(b) Management ’ s annual report on internal control over financial reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act.

Under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, we conducted an evaluation of the effectiveness, as of March 31, 2024, of our internal control over financial reporting based on the framework in 2013 Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.

Based on our evaluation under this framework, our management concluded that our internal control over financial reporting was effective as of March 31, 2024.

Our Management, including our Chief Executive Officer and Principal Financial Officer, evaluated our “internal control over financial reporting” as defined in Exchange Act Rule 13a-15(f) to determine whether any changes in our internal control over financial reporting occurred during Fiscal 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Based on that evaluation, there were no changes in our internal control over financial reporting during Fiscal 2024 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Evaluation of disclosure controls and procedures

Management maintains disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act

of 1934 (the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed in our reports

filed or submitted under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC’s

rules and forms, and that such information is accumulated and communicated to Management, including our Chief Executive Officer (our

principal executive officer) and Principal Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.

Management conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered

by this report.

Based on this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls

and procedures were effective to ensure that the information required to be disclosed in the reports filed or submitted by us under the

Exchange Act was recorded, processed, summarized and reported within the requisite time periods specified in SEC rules and forms and

that such information was accumulated and communicated to our Management, including our Chief Executive Officer and Principal Financial

Officer, as appropriate to allow for timely decisions regarding required disclosure.

Management ’ s annual report on internal control over financial reporting

management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined

in Rules 13a-15(f) and 15d-15(f) under the Exchange Act.

Under the supervision and with the participation of our management, including

our Principal Executive Officer and Principal Financial Officer, we conducted an evaluation of the effectiveness, as of March 31, 2025,

of our internal control over financial reporting based on the framework in 2013 Internal Control - Integrated Framework issued by the

Committee of Sponsoring Organizations of the Treadway Commission.

Based on our evaluation under this framework, our management concluded

that our internal control over financial reporting was effective as of March 31, 2025.

Changes in internal control over financial reporting

Management, including our Chief Executive Officer and Principal Financial Officer, evaluated our “internal control over financial

reporting” as defined in Exchange Act Rule 13a-15(f) to determine whether any changes in our internal control over financial reporting

occurred during Fiscal 2025 that materially affected, or are reasonably likely to materially affect, our internal control over financial

Based on that evaluation, there were no changes in our internal control over financial reporting during Fiscal 2025 that have

materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Other Information

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not Applicable.

DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

Information about our executive officers and directors

The names, ages, and positions of our executive officers and directors as of March 31, 2024, were as follows:

Director Since

Term will Expire

President, Chief Executive Officer, and Director

about our executive officers and directors

names, ages, and positions of our executive officers and directors as of March 31, 2025, were as follows:

President, Chief Executive

Officer, and Director

Richard Prins

3 unchanged sentences

Claudia Grimaldi

Vice President, Principal Financial Officer, Chief Compliance Officer, and Director

The principal occupations for the past five years (and, in some instances, for prior years) of each of our executive officers and directors are as follows:

Ram Mukunda has served as Director, CEO, and President since April 29, 2005.

He is responsible for general management and, over the past nine years, has been largely responsible for the Company’s strategy and positioning in the medical cannabinoids and pharmaceutical industry.

He has been the chief inventor and architect of most of the Company’s patent filings and the thrust into R&D and medical trials, which support the Company’s desire to bring low-cost medications that address diseases and ailments that affect humankind.

Prior to IGC, from January 1990 to May 2004, Mr.

Mukunda served as Founder and CEO of Startec Global Communications, which he took public in 1997 on NASDAQ.

Prior to Startec, he served as a Strategic Planning Advisor at Intelsat, a communications satellite services provider and prior to that worked in the bond market for a boutique firm on Wall Street.

Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering.

From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs.

Mukunda is the recipient of several awards including, among others, the 2013 University of Maryland’s International Alumnus of the year award, the 2001 Distinguished Engineering Alumnus Award, the 1998 Ernst & Young, LLP’s Entrepreneur of the Year Award.

Vice President, Principal Financial

Officer, Chief Compliance Officer, and Director

principal occupations for the past five years (and, in some instances, for prior years) of each of our executive officers and directors

are as follows:

Mukunda has served as Founder, Director, CEO, and President since inception.

He is responsible for general management and, over the

past 11 years, has been largely responsible for the Company’s strategy and positioning in the pharmaceutical industry.

the chief inventor and architect of most of the Company’s patent filings and the thrust into R&D and medical trials, which

support the Company’s desire to bring low-cost medications that address diseases and ailments that affect humankind.

Prior to IGC,

from January 1990 to May 2004, Mr.

Mukunda served as Founder and CEO of Startec Global Communications, which he took public in 1997 on

Prior to Startec, he served as a Strategic Planning Advisor at Intelsat, a communications satellite services provider and prior

to that worked in the bond market for a boutique firm on Wall Street.

Mukunda serves as an Emeritus member on the Board of Visitors

at the University of Maryland, School of Engineering.

From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of

Government, Belfer Center of Science and International Affairs.

Mukunda is the recipient of several awards including, among others,

the 2013 University of Maryland’s International Alumnus of the year award, the 2001 Distinguished Engineering Alumnus Award, the

1998 Ernst & Young, LLP’s Entrepreneur of the Year Award.

He holds a B.S.

degree in Electrical Engineering, a B.S.

degree in Mathematics, and a M.S.

Mathematics, and a M.S.

in Engineering from the University of Maryland.

Mukunda has traveled extensively and managed companies in Europe and Asia.

Mukunda has traveled extensively and managed companies in

Europe and Asia.

He has over 25 years of experience managing public companies and has acquired and integrated over 20 companies.

His in-depth business experience in the medical cannabinoids industry, his knowledge of U.S.

capital markets, capital structuring, international joint ventures, and broad science and engineering background make him qualified to serve as a director of our Company.

Richard Prins has been our Chairman, Audit Committee, and Compensation Committee Chairman since 2012 and has served as an Independent Director since May 2007.

in-depth business experience in the pharmaceutical and OTC industries, his knowledge of U.S.

capital markets, capital structuring, international

joint ventures, and broad science and engineering background make him qualified to serve as a director of our Company.

Prins has been our Chairman, Audit Committee, and Compensation Committee Chairman since 2012 and has served as an Independent Director

since May 2007.

Prins has extensive experience in private equity investing and investment banking.

From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated (“FBW”).

Prins served in a consulting role for RBC until January 2009.

From March 1996 to 2008, he was

the Director of Investment Banking at Ferris, Baker Watts, Incorporated (“FBW”).

Prins served in a consulting role for

RBC until January 2009.

Since February 2003, he has been on the board of Amphastar Pharmaceuticals, Inc.

Prins holds a B.A.

degree from Colgate University and an M.B.A.

from Colgate University and an M.B.A.

from Oral Roberts University.

Prins has substantial knowledge and experience with U.S.

capital markets, has served on and chaired audit and compensation committees of boards, and has extensive experience in finance, accounting, and internal controls over financial reporting.

markets, has served on and chaired audit and compensation committees of boards, and has extensive experience in finance, accounting,

and internal controls over financial reporting.

His knowledge of the pharmaceutical industry and experience with U.S.

capital markets make him qualified to serve as a director of our Company.

James Moran (Congressman Moran) has served on the Board as an Independent Director since January 2022.

He served on Virginia’s 8th Congressional District for 24 years, where he was known as a “Problem Solver.” Throughout his tenure, he demonstrated bipartisan leadership and worked across the aisle to find common ground to resolve complex issues.

He served on the Appropriation, Banking and Finance, and Budget committees.

capital markets

make him qualified to serve as a director of our Company.

Moran (Congressman Moran) has served on the Board as an Independent Director since January 2022.

He served on Virginia’s 8th

Congressional District for 24 years, where he was known as a “Problem Solver.” Throughout his tenure, he demonstrated bipartisan

leadership and worked across the aisle to find common ground to resolve complex issues.

He served on the Appropriation, Banking and Finance,

and Budget committees.

He played a leadership role in the areas of defense, health, and the environment.

During his 24 years in Congress, Congressman Moran was recognized as a champion of innovative research and development in areas including healthcare and national security, environmental protection and sustainability, and international trade and fiscal responsibility.

He rose to senior leadership on the Appropriations Committee enabling him to bring billions of dollars into his Northern Virginia communities of Alexandria, Arlington, and Fairfax County.

Having retired after 35 years in elected office, Congressman Moran is now with a major law firm and represents international and domestic clients in the defense, technology, entertainment, and international diplomacy sectors.

He also serves in leadership roles for several non-profit foundations and is also a member of the Government Blockchain Association.

Congressman Moran received a Master’s Degree in Public Administration from the University of Pittsburgh Graduate School of Public and International Affairs and a Bachelors in Economics from the College of the Holy Cross.

Congressman Moran introduced the AUTISM Educators Act in 2012, which funded partnerships between public schools and higher education and non-profit organizations to promote teaching skills for educators working with high functioning autism students.

He understands that treatment and education for conditions such as Autism and Alzheimer’s disease have the potential to positively impact millions of lives.

With his extensive experience in Congress and as a policy advisor on topics including health, technology, and education, we are confident Congressman Moran will be a great asset to IGC, especially at a time when we pursue Phase 2/3 human trials on IGC- AD1 on individuals that have Alzheimer’s disease.

Congressman Moran’s extensive experience makes him qualified to serve as a director of our Company.

On December 27, 2022, the Board of Directors appointed Mr.

James Moran as a member of both the Company’s Audit and Compensation Committee, effective immediately.

During his 24 years in Congress,

Congressman Moran was recognized as a champion of innovative research and development in areas including healthcare and national security,

environmental protection and sustainability, and international trade and fiscal responsibility.

He rose to senior leadership on the Appropriations

Committee enabling him to bring billions of dollars into his Northern Virginia communities of Alexandria, Arlington, and Fairfax County.

Having retired after 35 years in elected office, Congressman Moran is now with a major law firm and represents international and domestic

clients in the defense, technology, entertainment, and international diplomacy sectors.

He also serves in leadership roles for several

non-profit foundations and is also a member of the Government Blockchain Association.

Congressman Moran received a Master’s Degree

in Public Administration from the University of Pittsburgh Graduate School of Public and International Affairs and a Bachelors in Economics

from the College of the Holy Cross.

Moran introduced the AUTISM Educators Act in 2012, which funded partnerships between public schools and higher education and non-profit

organizations to promote teaching skills for educators working with high functioning autism students.

He understands that treatment and

education for conditions such as Autism and Alzheimer’s disease have the potential to positively impact millions of lives.

his extensive experience in Congress and as a policy advisor on topics including health, technology, and education, we are confident

Congressman Moran will be a great asset to IGC, especially at a time when we pursue Phase 2/3 human trials on IGC- AD1 on individuals

that have Alzheimer’s disease.

Congressman Moran’s extensive experience makes him qualified to serve as a director of our

December 27, 2022, the Board of Directors appointed Mr.

James Moran as a member of both the Company’s Audit and Compensation Committee,

effective immediately.

Lierman has served on the Board as an Independent Director since March 2024.

Lierman is currently Co-Chair of the Board of Advisors at the Institute of Human Virology (“IHV”), a center in the U.S.

focused on accelerating the discovery of diagnostics and therapeutics for deadly viral and immune disorders, and a member of the Board of Visitors at the La Follette School of Public Affairs at the University of Wisconsin, his alma mater.

Lierman founded the Children’s Research Institute, one of America’s top children’s research programs, the Pancreatic Cancer Action Network (“PanCAN”), and the National Organization on Fetal Alcohol Syndrome (“NOFAS”).

Lierman is currently Co-Chair of the Board of

Advisors at the Institute of Human Virology (“IHV”), a center in the U.S.

focused on accelerating the discovery of diagnostics

and therapeutics for deadly viral and immune disorders, and a member of the Board of Visitors at the La Follette School of Public Affairs

at the University of Wisconsin, his alma mater.

Lierman founded the Children’s Research Institute, one of America’s top

children’s research programs, the Pancreatic Cancer Action Network (“PanCAN”), and the National Organization on Fetal

Alcohol Syndrome (“NOFAS”).

In addition, from 1987 to 1999, he served as a director/trustee of the NY Life-Mainstay Funds.

His distinguished career includes serving at the National Institutes of Health (“NIH”), as the chief administrator for drug research and development at the National Cancer Institute (“NCI”), and as the Staff Director for the Committee on Appropriations at the U.S.

His distinguished career includes serving at the National Institutes of Health (“NIH”), as the chief administrator for drug

research and development at the National Cancer Institute (“NCI”), and as the Staff Director for the Committee on Appropriations

Senate and the Chief of Staff and White House liaison to the U.S.

House of Representative’s Majority Leader.

Lierman’s vast healthcare expertise will undoubtedly play a pivotal role in driving our mission to develop innovative therapeutics for crucial unmet needs.

vast healthcare expertise will undoubtedly play a pivotal role in driving our mission to develop innovative therapeutics for crucial

His extensive experience uniquely qualifies him to serve as a director of our company.

Claudia Grimaldi , Vice-president, PFO, Chief Compliance Officer, and Director, is responsible for managing the accounting and finance teams in various countries and is responsible for ensuring timely and accurate statutory and regulatory compliance (SEC, FINRA, NYSE, IRS, XETRA 2, among others).

In addition, she is responsible for building and managing an international team of doctors, scientists, and advisors that conduct and manage pre-clinical and FDA registered trials focused on Alzheimer’s disease.

She is also responsible for relationships with partners that provide, among others, animal studies, cannabinoids, and software for AI.

She has more than thirteen (13) years of experience with SEC filings, regulatory compliance, and disclosures, having held increasing responsibilities first as Manager of financial reporting and compliance from May 2011 to 2013 and then as General Manager financial reporting and compliance from 2013 to May 2018.

Grimaldi , Vice-president, PFO, Chief Compliance Officer, and Director, is responsible for managing the accounting and finance teams

in various countries and is responsible for ensuring timely and accurate statutory and regulatory compliance (SEC, FINRA, NYSE, IRS,

XETRA 2, among others).

In addition, she is responsible for building and managing an international team of doctors, scientists, and advisors

that conduct and manage pre-clinical and FDA registered trials focused on Alzheimer’s disease.

She is also responsible for relationships

with partners that provide, among others, animal studies, cannabinoids, and software for AI.

She has more than thirteen (13) years of

experience with SEC filings, regulatory compliance, and disclosures, having held increasing responsibilities first as Manager of financial

reporting and compliance from May 2011 to 2013 and then as General Manager of financial reporting and compliance from 2013 to May 2018.

She also serves as a Director/Manager for some of our subsidiaries.

Grimaldi graduated summa cum laude from Javeriana University, a top five university in Colombia, with a Bachelor of Arts in Psychology.

She holds an MBA in General Management, graduating with Highest Honors, from Meredith College, in North Carolina.

Grimaldi graduated summa cum laude from Javeriana University,

a top five university in Colombia, with a Bachelor of Arts in Psychology.

She holds an MBA in General Management, graduating with Highest

Honors, from Meredith College, in North Carolina.

She is a member of Delta Mu Delta International Honor Society.

She has also completed Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School.

In addition, she has attended the Darden School of Business Financial Management Executives program at the University of Virginia, and SEC reporting and compliance seminars.

She has also completed

Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School.

she has attended the Darden School of Business Financial Management Executives program at the University of Virginia, and SEC reporting

and compliance seminars.

She also completed her certification program of the National Association of Corporate Directors (NACD).

She is also fluent in both English and Spanish.

On August 18, 2023, the Board of Directors of the Company elected Ms.

Claudia Grimaldi to serve on the Board as a non-independent director Class A until the Company’s 2026 annual meeting of stockholders upon the election and qualification of successor directors, her earlier death, resignation, or removal.

Grimaldi brings a wealth of experience and qualifications that make her an excellent fit for the board.

Grimaldi’s experience with SEC filing procedures is invaluable in ensuring regulatory compliance and transparency within our public company.

Additionally, her in-depth understanding of Colombia, and South America-where our company has invested in human capital, provides valuable insights into the market dynamics, cultural nuances, and business opportunities within the region.

Her SEC filing experience, understanding of Colombia, qualifications in business administration, and general business acumen make her qualified to serve as a director of our Company.

Executive officers are appointed by our Board of Directors.

Each executive officer holds his or her office until he or she resigns or is removed by the Board or his or her successor is elected and qualified.

All directors hold office until the annual meeting of the stockholders in the year set forth above in the table and until their successors have been duly elected or qualified.

There are no family relationships between any of our executive officers or directors.

For information on legal proceedings against the Company or its officers and executive directors, please refer to Item 3.

is also fluent in both English and Spanish.

August 18, 2023, the Board of Directors of the Company elected Ms.

Claudia Grimaldi to serve on the Board as a non-independent director

Class A until the Company’s 2026 annual meeting of stockholders upon the election and qualification of successor directors, her

earlier death, resignation, or removal.

Grimaldi brings a wealth of experience and qualifications that make her an excellent fit

for the board.

Grimaldi’s experience with SEC filing procedures is invaluable in ensuring regulatory compliance and transparency

within our public company.

Additionally, her in-depth understanding of Colombia, and South America where our company has invested in

human capital, provides valuable insights into the market dynamics, cultural nuances, and business opportunities within the region.

SEC filing experience, understanding of Colombia, qualifications in business administration, and general business acumen make her qualified

to serve as a director of our Company.

officers are appointed by our Board of Directors.

Each executive officer holds his or her office until he or she resigns or is removed

by the Board or his or her successor is elected and qualified.

All directors hold office until the annual meeting of the stockholders

in the year set forth above in the table and until their successors have been duly elected or qualified.

There are no family relationships

between any of our executive officers or directors.

For information on legal proceedings against the Company, please refer to Item 3.

Legal Proceedings.

Board of directors and independence

Our Board of Directors is divided into three classes (Class A, Class B, and Class C) with only one class of directors being elected each year and each class serving a three-year term.

The term of office of the Class A director, consisting of Claudia Grimaldi, will expire at the 2026 annual meeting of stockholders.

The term of office of the Class B director, currently consisting of Richard Prins and Terry L.

There are currently no legal proceedings against the Company’s directors or officers.

McAuliffe, served as an Advisor since December 2024.

He was sworn in as governor of Virginia on January 11, 2014.

He is a businessman,

entrepreneur and who lived in Fairfax County, Virginia, for more than 20 years.

In politics and business, McAuliffe has worked with people

from all walks of life and different political backgrounds.

(Ret.) Howard Gutman, serves as a strategic advisor to IGC Pharma Inc., bringing extensive experience in international law, diplomacy,

and public policy.

He served as the U.S.

Ambassador to Belgium from 2009 to 2013 and has had a distinguished career in both government

and private sector advisory roles.

Ambassador Gutman contributes to IGC’s corporate strategy and global partnership initiatives,

leveraging his expertise in regulatory, political, and international affairs.

Chuanhai Cao, Ph.D., is a scientific advisor to IGC Pharma Inc., with deep expertise in neuroimmunology and Alzheimer’s disease

He is an Associate Professor at the University of South Florida’s Morsani College of Medicine and College of Pharmacy.

His work focuses on the therapeutic potential of cannabinoids and immune modulation in neurodegenerative conditions.

research contributions align closely with IGC’s mission to develop innovative treatments for Alzheimer’s disease.

Saunders, Ph.D., is a scientific advisor to IGC Pharma Inc., bringing decades of academic and research experience in biotechnology

and plant sciences.

He has held faculty and leadership roles at respected academic institutions and has contributed to numerous peer-reviewed

publications.

Saunders provides guidance on natural compounds and their therapeutic potential, supporting IGC’s research

in cannabinoid-based treatments for Alzheimer’s disease.

Hong, M.D., is a scientific advisor to IGC Pharma Inc., offering expertise in translational neuroscience and psychiatric

He is a professor of psychiatry at the University of Maryland School of Medicine and a leading investigator in the fields of

brain imaging, schizophrenia, and neurodevelopment.

Hong’s insights support IGC’s efforts to develop therapeutics for

neuropsychiatric symptoms associated with Alzheimer’s disease.

Cummings, M.D., Sc.D.

, serves as a scientific advisor to IGC Pharma Inc.

He is a world-renowned neurologist and expert

in Alzheimer’s disease research, drug development, and clinical trials.

Cummings is the founding director of the Cleveland

Clinic Lou Ruvo Center for Brain Health and a Research Professor at the University of Nevada, Las Vegas.

His contributions support IGC’s

mission to advance innovative therapies for neurodegenerative diseases through expert guidance in clinical strategy and trial design.

Pablo Arbeláez is a scientific advisor to IGC Pharma, contributing expertise in biomedical image analysis and artificial intelligence.

He is a professor at Universidad de los Andes in Colombia and a former researcher at École Normale Supérieure in Paris.

Arbeláez’s research focuses on deep learning in medical imaging and its application to neurodegenerative diseases, aligning

with IGC’s mission to develop innovative therapies for Alzheimer’s disease.

of directors and independence

Board of Directors is divided into three classes (Class A, Class B, and Class C) with only one class of directors being elected each

year and each class serving a three-year term.

The term of office of the Class A director, consisting of Claudia Grimaldi, will expire

at the 2026 annual meeting of stockholders.

The term of office of the Class B director, currently consisting of Richard Prins and Terry

Lierman, will expire at the 2027 annual meeting of stockholders.

The term of office of the Class C director, currently consisting of Ram Mukunda and James Moran, will expire at the 2025 annual meeting of stockholders.

These individuals have played a key role in identifying and evaluating prospective acquisition candidates, selecting the target businesses, and structuring, negotiating, and consummating acquisitions.

The NYSE American, upon which our shares are listed, requires the majority of our Board, or in the case of a smaller reporting Company, at least 50% of our Board, to be “independent.” The NYSE American listing standards define an “independent director” generally as a person, other than an officer or an employee of the Company, who does not have a relationship with the Company that would interfere with the director’s exercise of independent judgment.

Consistent with these standards, the Board of Directors has determined that Messrs.

The term of office of the Class C director, currently consisting

of Ram Mukunda and James Moran, will expire at the 2025 annual meeting of stockholders.

These individuals have played a key role in identifying

and evaluating prospective acquisition candidates, selecting the target businesses, and structuring, negotiating, and consummating acquisitions.

NYSE American, upon which our shares are listed, requires the majority of our Board, or in the case of a smaller reporting Company, at

least 50% of our Board, to be “independent.” The NYSE American listing standards define an “independent director”

generally as a person, other than an officer or an employee of the Company, who does not have a relationship with the Company that would

interfere with the director’s exercise of independent judgment.

Consistent with these standards, the Board of Directors has determined

Prins, Moran, and Lierman are independent directors.

Board leadership structure

The Board believes its current leadership structure best serves the objectives of the Board’s oversight of management, the Board’s ability to carry out its roles and responsibilities on behalf of IGC’s shareholders, and IGC’s overall corporate governance.

The Board also believes that the separation of the Chairman and CEO roles allows the CEO to focus his time and energy on operating and managing IGC, while leveraging the Chairman’s experience and perspectives.

The Board periodically reviews its leadership structure to determine whether it continues to best serve IGC and its shareholders.

Board oversight of risk management

The Board is responsible for overseeing the major risks facing the Company, while management is responsible for assessing and mitigating the Company’s risks on a day-to-day basis.

The Board has designated the Audit Committee with the responsibility for overseeing enterprise risk management.

leadership structure

Board believes its current leadership structure best serves the objectives of the Board’s oversight of management, the Board’s

ability to carry out its roles and responsibilities on behalf of IGC’s shareholders, and IGC’s overall corporate governance.

The Board also believes that the separation of the Chairman and CEO roles allows the CEO to focus his time and energy on operating and

managing IGC, while leveraging the Chairman’s experience and perspectives.

The Board periodically reviews its leadership structure

to determine whether it continues to best serve IGC and its shareholders.

oversight of risk management

Board is responsible for overseeing the major risks facing the Company, while management is responsible for assessing and mitigating

the Company’s risks on a day-to-day basis.

The Board has designated the Audit Committee with the responsibility for overseeing

enterprise risk management.

The Audit Committee discusses the steps management has taken to monitor and mitigate these risks, if any.

In establishing and reviewing IGC’s executive compensation, the Compensation Committee considers whether the compensation program is focused on long-term shareholder value creation and whether it encourage short-term risk taking at the expense of long-term results.

The Compensation Committee has also reviewed IGC’s compensation program and has concluded that these programs do not create risks that are reasonably likely to have a material adverse effect on IGC.

Other Board committees also consider risks within their areas of responsibility and apprise the Board of significant risks and management’s response to those risks.

Audit committee

Our Board of Directors has established an Audit Committee, currently composed of two independent directors who report to the Board of Directors.

Prins and Moran, each of whom is an independent director under the NYSE American listing standards, serve as members of our Audit Committee.

In establishing and reviewing IGC’s executive compensation, the Compensation Committee considers whether the compensation program

is focused on long-term shareholder value creation and whether it encourages short-term risk taking at the expense of long-term results.

The Compensation Committee has also reviewed IGC’s compensation program and has concluded that these programs do not create risks

that are reasonably likely to have a material adverse effect on IGC.

Other Board committees also consider risks within their areas of

responsibility and apprise the Board of significant risks and management’s response to those risks.

Board of Directors has established an Audit Committee, currently composed of two independent directors who report to the Board of Directors.

Prins and Moran, each of whom is an independent director under the NYSE American listing standards, serve as members of our Audit

Prins is the Chairman of our Audit Committee.

In addition, we have determined that Messrs.

Prins and Moran are “audit committee financial experts,” as that term is defined under Item 407 of Regulation S-K.

The Audit Committee is responsible for meeting with our independent accountants regarding, among other issues, audits and the adequacy of our accounting and control systems.

Prins and Moran are “audit

committee financial experts,” as that term is defined under Item 407 of Regulation S-K.

The Audit Committee is responsible for

meeting with our independent accountants regarding, among other issues, audits and the adequacy of our accounting and control systems.

The audit committee charter is followed by the committee.

Compensation committee

Our Board of Directors has established a Compensation Committee composed of two independent directors, Messrs.

Board of Directors has established a Compensation Committee composed of two independent directors, Messrs.

Moran and Prins.

Prins is the current Chairman of our Compensation Committee.

The Compensation Committee’s purpose is to review and approve the compensation paid to our officers and directors and to administer our 2018 Omnibus Incentive Plan.

As per the compensation committee charter, candidate experience, knowledge, and performance are used to evaluate the candidate.

The compensation is accordingly decided for the candidate as per the industry standards.

Compensation committee interlocks and insider participation

Our Compensation Committee is comprised of two independent members of the Board of Directors, Richard Prins and James Moran.

No executive officer of the Company served as a director or member of the Compensation Committee of any other entity.

The Compensation Committee was responsible for determining executive compensation and the award of stock and stock options to employees, advisors, and directors during Fiscal 2024.

is the current Chairman of our Compensation Committee.

The Compensation Committee’s purpose is to review and approve the compensation

paid to our officers and directors and to administer our 2018 Omnibus Incentive Plan.

As per the compensation committee charter, candidate

experience, knowledge, and performance are used to evaluate the candidate.

The compensation is accordingly decided for the candidate

as per the industry standards.

committee interlocks and insider participation

Compensation Committee is comprised of two independent members of the Board of Directors, Richard Prins and James Moran.

officer of the Company served as a director or member of the Compensation Committee of any other entity.

The Compensation Committee was

responsible for determining executive compensation and the award of stock and stock options to employees, advisors, and directors during

No consultants were used by the Compensation Committee during this fiscal year.

Nominating and corporate governance committee

In the future, we intend to establish a nominating and corporate governance committee.

The primary purpose of the nominating and corporate governance committee will be to identify individuals qualified to become directors, recommend to the Board of Directors the candidates for election by stockholders or appointment by the Board of Directors to fill a vacancy, recommend to the Board of Directors the composition and chairs of Board of Directors committees, develop and recommend to the Board of Directors guidelines for effective corporate governance, and lead an annual review of the performance of the Board of Directors and each of its committees.

We do not have any formal process for stockholders to nominate a director for election to our Board of Directors.

Currently, nominations are selected or recommended by a majority of the independent directors as stated in Section 804(a) of the NYSE American Company Guide.

Since the Company is a small reporting company with limited officers and directors, the committee currently does not have a nomination committee charter.

The Board of Director nominations occur by either selection or recommendation of a majority of the independent directors.

Disclosure Committee

The CEO and the PFO supervise and oversee the Disclosure Committee.

and corporate governance committee

the future, we intend to establish a nominating and corporate governance committee.

The primary purpose of the nominating and corporate

governance committee will be to identify individuals qualified to become directors, recommend to the Board of Directors the candidates

for election by stockholders or appointment by the Board of Directors to fill a vacancy, recommend to the Board of Directors the composition

and chairs of Board of Directors committees, develop and recommend to the Board of Directors guidelines for effective corporate governance,

and lead an annual review of the performance of the Board of Directors and each of its committees.

We do not have any formal process

for stockholders to nominate a director for election to our Board of Directors.

Currently, nominations are selected or recommended by

a majority of the independent directors as stated in Section 804(a) of the NYSE American Company Guide.

Since the Company is a small

reporting company with limited officers and directors, the committee currently does not have a nomination committee charter.

of Director nominations occur by either selection or recommendation of a majority of the independent directors.

CEO and the PFO supervise and oversee the Disclosure Committee.

The Board has appointed Mr.

Richard Prins as the Chairperson of the Disclosure Committee.

The Disclosure Committee’s responsibilities are to design, implement, and regularly evaluate the Company’s internal controls and procedures, to ensure that the company provides the stakeholders, including the Securities and Exchange Commission (“SEC”), security holders, and the investment community, disclosures that comply with regulations and other compliance obligations.

The Disclosure Committee will review all required material and relevant reports related to disclosure statements, including annual reports on Form 10-K, quarterly reports on Form 10-Q, press releases, and social media containing financial information and other related public documents.

The Disclosure Committee meets not less than once per quarter and reviews and reassesses the adequacy of the Disclosure Committee’s Charter at least annually.

Audit Committee Financial Expert

The Audit Committee will at all times be composed exclusively of “independent directors” who are “financially literate,” as defined under the NYSE American listing standards, who understand the audit committee functions.

The NYSE American’s listing standards define “financially literate” as being able to read and understand fundamental financial statements, including a company’s balance sheet, income statement, and cash flow statement.

In addition, we must certify to the NYSE American that the Audit Committee has, and will continue to have, at least one member who has past employment experience in finance, accounting, or auditing, requisite professional certification in accounting, or other comparable experience or background that results in the individual’s financial sophistication, along with an understanding of internal control over financial reporting.

The Board of Directors has determined that Messrs.

Prins and Moran satisfy the NYSE American’s definition of financial sophistication and qualify as “audit committee financial experts,” as defined under the rules and regulations of the SEC.

Board and committee meetings

During Fiscal 2024, there were twelve (12) Board meetings, five (5) meetings of the Audit Committee, two (2) Compensation Committee meetings, and one (1) meeting of the Investment Committee, all of which were attended, either in person or telephonically, by all our directors of the Board and all of the members of the committees, respectively.

Communications with the Board

Any matter intended for the Board or any individual member of the Board should be directed to Investor Relations at the Company’s principal executive office, with a request to forward the communication to the intended recipient.

In general, any shareholder communication delivered to the Company for forwarding to Board members will be forwarded in accordance with the shareholder’s instructions.

However, the Company reserves the right not to forward to Board members any abusive, threatening, or otherwise inappropriate materials.

Indemnification agreements

We are party to indemnification agreements with each of the executive officers and directors.

Such indemnification agreements require us to indemnify these individuals to the fullest extent permitted by law.

Under the terms of the indemnification agreements, we intend to agree to indemnify our officers and directors against expenses, judgments, fines, penalties, or other amounts actually and reasonably incurred by the independent director in connection with any proceeding if the officer or director acted in good faith and did not derive an improper personal benefit from the transaction or occurrence that is the basis of the proceeding.

Annual meeting attendance

All directors, either in person or telephonically, attended the 2023 annual shareholder’s meeting.

We have a formal policy requiring the members of our Board of Directors to attend annual stockholder meetings in person or by telephone or video conference.

Corporate governance, code of conduct, and ethics

A code of business conduct and ethics is a written standard designed to deter wrongdoing and to promote (a) honest and ethical conduct, (b) full, fair, accurate, timely, and understandable disclosure in regulatory filings and public statements, (c) compliance with applicable laws, rules, and regulations, (d) the prompt reporting violation of the code and (e) accountability for adherence to the code.

The Company has adopted a written code of ethics (the “Code of Ethics”) that applies to the Company’s Chief Executive Officer and senior financial officers, including the Company’s Principal Accounting Officer, Controller, and persons performing similar functions (collectively, the “Senior Financial Officers”), in accordance with applicable federal securities laws and the rules of the NYSE American, and to all employees.

Investors or any other person may view our Code of Ethics free of charge on the corporate governance subsection of the investor relations portion of our website at www.igcinc.us.

The Company has established separate audit and compensation committees that are described elsewhere in this report.

Richard Prins as the Chairperson of the Disclosure

The Disclosure Committee’s responsibilities are to design, implement, and regularly evaluate the Company’s internal

controls and procedures, to ensure that the company provides the stakeholders, including the Securities and Exchange Commission (SEC),

security holders, and the investment community, disclosures that comply with regulations and other compliance obligations.

The Disclosure

Committee will review all required material and relevant reports related to disclosure statements, including annual reports on Form 10-K,

quarterly reports on Form 10-Q, press releases, and social media containing financial information and other related public documents.

The Disclosure Committee meets not less than once per quarter and reviews and reassesses the adequacy of the Disclosure Committee’s

Charter at least annually.

Committee Financial Expert

Audit Committee will at all times be composed exclusively of “independent directors” who are “financially literate,”

as defined under the NYSE American listing standards, who understand the audit committee functions.

The NYSE American’s listing

standards define “financially literate” as being able to read and understand fundamental financial statements, including

a company’s balance sheet, income statement, and cash flow statement.

In addition, we must certify to the NYSE American that the

Audit Committee has, and will continue to have, at least one member who has past employment experience in finance, accounting, or auditing,

requisite professional certification in accounting, or other comparable experience or background that results in the individual’s

financial sophistication, along with an understanding of internal control over financial reporting.

The Board of Directors has determined

Prins and Moran satisfy the NYSE American’s definition of financial sophistication and qualify as “audit committee

financial experts,” as defined under the rules and regulations of the SEC.

and committee meetings

Fiscal 2025, there were six (6) Board meetings, five (5) meetings of the Audit Committee, and two (2) Compensation Committee meetings,

all of which were attended, either in person or telephonically, by all our directors of the Board and all of the members of the committees,

respectively.

Communications

with the Board

matter intended for the Board or any individual member of the Board should be directed to Investor Relations at the Company’s principal

executive office, with a request to forward the communication to the intended recipient.

In general, any shareholder communication delivered

to the Company for forwarding to Board members will be forwarded in accordance with the shareholder’s instructions.

Company reserves the right not to forward to Board members any abusive, threatening, or otherwise inappropriate materials.

Indemnification

are party to indemnification agreements with each of the executive officers and directors.

Such indemnification agreements require us

to indemnify these individuals to the fullest extent permitted by law.

Under the terms of the indemnification agreements, we intend to

agree to indemnify our officers and directors against expenses, judgments, fines, penalties, or other amounts actually and reasonably

incurred by the independent director in connection with any proceeding if the officer or director acted in good faith and did not derive

an improper personal benefit from the transaction or occurrence that is the basis of the proceeding.

meeting attendance

directors, either in person or telephonically, attended the 2024 annual shareholder’s meeting.

We have a formal policy requiring

the members of our Board of Directors to attend annual stockholder meetings in person or by telephone or video conference.

governance, code of conduct, and ethics

code of business conduct and ethics is a written standard designed to deter wrongdoing and to promote (a) honest and ethical conduct,

(b) full, fair, accurate, timely, and understandable disclosure in regulatory filings and public statements, (c) compliance with applicable

laws, rules, and regulations, (d) the prompt reporting violation of the code and (e) accountability for adherence to the code.

has adopted a written code of ethics (the “Code of Ethics”) that applies to the Company’s Chief Executive Officer and

senior financial officers, including the Company’s Principal Accounting Officer, Controller, and persons performing similar functions

(collectively, the “Senior Financial Officers”), in accordance with applicable federal securities laws and the rules of the

NYSE American, and to all employees.

Investors or any other person may view our Code of Ethics free of charge on the corporate governance

subsection of the investor relations portion of our website at www.igcinc.us.

The Company has established separate audit and compensation

committees that are described elsewhere in this report.

The Company does not have a separate nominating committee.

Accordingly, Board of Director nominations occur by either selection or recommendation of a majority of the independent directors.

All our data, except accounting data, is stored in the cloud on multiple servers, which helps us mitigate the overall risk of losing data.

As part of corporate governance, we also have a cybersecurity policy that employees are required to comply with to safeguard their systems from cyber-attacks.

Delinquent Section 16(a) reports

Section 16(a) of the Securities and Exchange Act of 1934, as amended, requires our officers, directors, and beneficial owners of more than 10% of our equity securities to timely file certain reports regarding ownership of and transactions in our securities with the Securities and Exchange Commission.

Accordingly, Board

of Director nominations occur by either selection or recommendation of a majority of the independent directors.

our data, except accounting data, is stored in the cloud on multiple servers, which helps us mitigate the overall risk of losing data.

As part of corporate governance, we also have a cybersecurity policy that employees are required to comply with to safeguard their systems

from cyber-attacks.

Trading Policy

have an insider trading policy governing the purchase, sale, and other dispositions of our securities (the “Insider Trading Policy”)

that applies to all of our directors, officers, employees, and other covered persons identified within the Insider Trading Policy.

believe that the Insider Trading Policy is reasonably designed to promote compliance with applicable U.S.

federal securities laws, rules,

and regulations, as well as applicable listing standards relating to insider trading.

In addition, with regard to our trading in our

own securities, it is our policy to comply with applicable federal securities laws and applicable listing requirements.

The Insider Trading

Policy is filed as Exhibit 19.1 to this Annual Report on Form 10-K.

Section 16(a) reports

16(a) of the Securities and Exchange Act of 1934, as amended, requires our officers, directors, and beneficial owners of more than 10%

of our equity securities to timely file certain reports regarding ownership of and transactions in our securities with the Securities

and Exchange Commission.

Copies of the required filings must also be furnished to us.

Section 16(a) compliance was required during Fiscal

Based solely on a review of Forms 3, 4, and 5 and amendments thereto furnished to us pursuant to Rule 16a-3(e) under the Exchange Act, we believe that Fiscal 2024’s filing requirements under Section 16(a) of the Exchange Act have been satisfied, except for (1) a Form 3 for Bradbury Strategic Investment Fund A filed May 15, 2024 reporting a person becoming a 5% holder and (2) a Form 4 for Bradbury Strategic Investment Fund A filed May 15, 2024 reporting an acquisition of shares on March 13, 2024.

Based solely on a review of Forms 3, 4, and 5 and amendments thereto furnished to us pursuant to Rule 16a-3(e) under the Exchange

Act, we believe that Fiscal 2025’s filing requirements under Section 16(a) of the Exchange Act have been satisfied, except for

(1) a Form 5 for Claudia Grimaldi reporting the vesting of RSUs on March 31, 2025;

(2) a Form 5 for James Moran reporting the vesting

of RSUs on March 31, 2025, (3) a Form 5 for Ram Mukunda reporting the vesting of RSUs on March 31, 2025 and (4) a Form 5 for Richard

Prins reporting the vesting of RSUs on March 31, 2025.

EXECUTIVE COMPENSATION

Compensation for executive officers of the Company

The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by, or paid to (i) all individuals serving as the smaller reporting company’s principal executive officer or acting in a similar capacity during the last completed fiscal year (PEO), regardless of compensation level;

(ii) the smaller reporting company’s two most highly compensated executive officers other than the PEO who were serving as executive officers at the end of the last completed fiscal year and whose compensation exceeded $100,000 a year;

and (iii) up to two additional individuals for whom disclosure would have been provided pursuant to paragraph (ii) but for the fact that the individual was not serving as an executive officer of the smaller reporting company at the end of the last completed fiscal year.

Summary Compensation Table

(in thousands)

for executive officers of the Company

following table sets forth information concerning all cash and non-cash compensation awarded to, earned by, or paid to (i) all individuals

serving as the smaller reporting company’s principal executive officer or acting in a similar capacity during the last completed

fiscal year (PEO), regardless of compensation level;

(ii) the smaller reporting company’s two most highly compensated executive

officers other than the PEO who was serving as executive officers at the end of the last completed fiscal year and whose compensation

exceeded $100,000.

Compensation Table

Name and Principal Position

Stock Awards (2)

Other compensation (3)

Total Compensation

President and CEO

1 unchanged sentence

Vice President, CCO, and PFO

During Fiscal year ended March 31, 2024, the Company owes approximately $396 thousand to Mr.

Ram Mukunda and $240 thousand to Ms.

Claudia Grimaldi.

The Stock Awards represent the fair value of stock awards to the named executive officer as computed using the closing price at the day of grant or using an appropriate pricing model depending on the terms of the award.

The Stock Awards include vested and unvested grants of stock awards as reflected in the table titled “Stock Awards at Fiscal Year End.” This also includes two categories of Stock Awards that are set out in the tables titled “Performance- Based Stock Awards” and “Market Price-Based Stock Awards,” which account for approximately $689 thousand in fiscal 2024 and Nil in fiscal 2023.

Includes life insurance, 401 (k) contribution, health insurance(s) and other applicable compensation.

Compensation to Directors

(in thousands)

The following table shows, for fiscal 2024, the compensation awarded to, earned by, or paid to non-employee directors who served on the Board during the fiscal year.

Richard Prins

The Total Compensation represents the fair value of stock awards to the named director as computed using the closing price at the day of grant or using an appropriate pricing model depending on the terms of the award.

The Stock Awards include vested and unvested grants of stock awards as reflected in the table titled “Stock Awards at Fiscal Year End.”

The following table shows, for fiscal 2023, the compensation awarded to, earned by, or paid to non-employee directors who served on the Board during the fiscal year.

Number of Stock

Richard Prins

The Total Compensation represents the fair value of stock awards to the named director as computed using the closing price at the day of grant.

The Stock Awards include vested and unvested grants of stock awards as reflected in the table titled “Stock Awards at Fiscal Year End.”

Stock Awards at Fiscal Year End

(in thousands)

unvested Stock Awards (#)

Value of unvested

Stock Awards ($)

fiscal 2025, the outstanding bonus of Ram Mukunda of approximately $423 thousand and of Claudia Grimaldi of approximately $327 thousand

has been converted into performance-based bonuses and will be paid upon achieving the following milestones.

Completion of CALMA Phase

2 Clinical Trial;

Successful fundraising of at least $5 million via equity, debt, partnerships, or non-dilutive grants.

Stock Awards represent the fair value of stock awards to the named executive officer as computed using the closing price at the day of

grant or using an appropriate pricing model depending on the terms of the award.

The Stock Awards include vested and unvested grants

of stock awards as reflected in the table titled “Stock Awards at Fiscal Year End.” This also includes two categories

of Stock Awards that are set out in the tables titled “Performance-Based Stock Awards” and “Market Price-Based

Stock Awards,” which account for approximately $689 thousand in fiscal 2024 and Nil in fiscal 2025.

life insurance, 401 (k) contribution, health insurance(s), and other applicable compensation.

fiscal 2025, no compensation was awarded to, earned by, or paid to non-employee directors who served on the Board during the fiscal year.

Awards at Fiscal Year End

unvested Stock

Value of vested

Stock Awards in Fiscal Year ($)

Total Value of

Stock Awards ($)

in Fiscal Year

Claudia Grimaldi

Richard Prins

The Stock Awards reflect the grant date fair value, in accordance with Accounting Standards Codification (ASC) Topic 718, Compensation — Stock Compensation (formerly Statement of Financial Accounting Standards (SFAS) No.

123R) for awards pursuant to the Company’s equity incentive program.

Included in the tables above are two categories of Stock Awards:

(i) performance-based stock awards that are based on achieving milestones in the area of drug development;

Stock Awards reflect the grant date fair value, in accordance with Accounting Standards Codification (ASC) Topic 718, Compensation —

Stock Compensation (formerly Statement of Financial Accounting Standards (SFAS) No.

123R) for awards pursuant to the Company’s

equity incentive program.

in the tables above are two categories of Stock Awards:

(i) performance-based stock awards that are based on achieving milestones in

the area of drug development;

and (ii) market price-based awards, based on advancing the IGC stock price.

Both categories are set out in the two tables titled “Performance-Based Stock Awards” and “Market Price-Based Stock Awards.”

Employment contracts

Ram Mukunda has served as President and Chief Executive Officer of our Company since its inception.

On November 18, 2021, the Company, and Mr.

Mukunda has served as President and Chief Executive Officer of our Company since its inception.

On November 18, 2021, the Company, and

Mukunda entered into the 2021 CEO Employment Agreement that expires on November 17, 2026.

Pursuant to the 2021 CEO Employment Agreement, we pay Mr.

Pursuant to the 2021 CEO Employment Agreement,

Mukunda a base salary of $360,000 per year.

The Employment Agreement provides that the Board of Directors of our Company may review and update the targets and amounts for the net revenue and salary and contract bonuses on an annual basis.

Mukunda is entitled to benefits, including insurance, participation in company-wide 401(k), reimbursement of business expenses, 20 days of annual paid vacation, sick leave, domestic help, driver, cook, and a car (subject to partial reimbursement by Mr.

Mukunda of rental payments for the car and reimbursement of business expenses).

In the event of termination without cause, including a change of control, we would be required to pay Mr.

The Employment Agreement provides that the Board of Directors of our Company may

review and update the targets and amounts for the net revenue and salary and contract bonuses on an annual basis.

Mukunda is entitled

to benefits, including insurance, participation in company-wide 401(k), reimbursement of business expenses, 20 days of annual paid vacation,

sick leave, domestic help, driver, cook, and a car (subject to partial reimbursement by Mr.

Mukunda of rental payments for the car and

reimbursement of business expenses).

In the event of termination without cause, including a change of control, we would be required to

Mukunda 1.5 times the average of the total compensation as disclosed in the previous two 10-K filings prior to termination.

In addition, all unvested shares would be subject to immediate vesting.

Claudia Grimaldi has served as Vice President, Principal Financial Officer, Chief Compliance Officer, and Director of our subsidiaries since May 9, 2018.

addition, all unvested shares would be subject to immediate vesting.

Grimaldi has served as Vice President, Principal Financial Officer, Chief Compliance Officer, and Director of our subsidiaries since

On May 5, 2023, the Company and Ms.

Grimaldi entered into an Employment Agreement that expires on May 8, 2028 (the 2023 Employment Agreement).

Grimaldi entered into an Employment Agreement that expires on May 8, 2028 (the 2023

Employment Agreement).

Pursuant to the Employment Agreement, we pay Ms.

Grimaldi a base salary of $200,000 per year.

The Employment Agreement provides that the Company may review and update performance targets and contract bonuses on an annual basis.

Grimaldi is entitled to benefits, including insurance, participation in company-wide 401(k), reimbursement of business expenses, 20 days of annual paid vacation, sick leave, and a car (subject to partial reimbursement by Ms.

The Employment Agreement

provides that the Company may review and update performance targets and contract bonuses on an annual basis.

Grimaldi is entitled

to benefits, including insurance, participation in company-wide 401(k), reimbursement of business expenses, 20 days of annual paid vacation,

sick leave, and a car (subject to partial reimbursement by Ms.

Grimaldi for personal use of the car).

In the event of termination without cause, including a change of control, we would be required to pay Ms.

In the event of termination without

cause, including a change of control, we would be required to pay Ms.

Grimaldi 1.5 times her compensation.

In addition, unvested shares that would otherwise vest in a 12-month period would be subject to immediate vesting.

For non-employee directors, the Company has a standard compensation arrangement such as fees for committee service, service as chairman of the board, or a committee, and meeting attendance.

Compensation risk assessment

In setting compensation, the Compensation Committee considers the risks to our stockholders and to the achievement of our goals that may be inherent in our compensation programs.

The Compensation Committee reviewed and discussed its assessment with management and concluded that our compensation programs are within industry standards and are designed with the appropriate balance of risk and reward to align employees’ interests with those of our Company and do not incent employees to take unnecessary or excessive risks.

Although a portion of our executives’ and employees’ compensation is performance-based and “at risk,” we believe our compensation plans are appropriately structured and are not reasonably likely to result in a material adverse effect on our Company.

In addition, unvested shares

that would otherwise vest in a 12-month period would be subject to immediate vesting.

non-employee directors, the Company has a standard compensation arrangement such as fees for committee service, service as chairman of

the board, or a committee, and meeting attendance.

risk assessment

setting compensation, the Compensation Committee considers the risks to our stockholders and to the achievement of our goals that may

be inherent in our compensation programs.

The Compensation Committee reviewed and discussed its assessment with management and concluded

that our compensation programs are within industry standards and are designed with the appropriate balance of risk and reward to align

employees’ interests with those of our Company and do not incent employees to take unnecessary or excessive risks.

Although a portion

of our executives’ and employees’ compensation is performance-based and “at risk,” we believe our compensation

plans are appropriately structured and are not reasonably likely to result in a material adverse effect on our Company.

and practices related to the grant of equity awards close in time to the release of material nonpublic information

the Board nor the Compensation Committee takes material nonpublic information into account when determining the timing or terms of equity

awards, including with respect to options, nor do we time the disclosure of material nonpublic information for the purpose of affecting

the value of executive compensation.

Although we do not have a formal policy with respect to the timing of our equity award grants we

have generally granted such awards once a year to directors and executive officers and equity awards may be granted at other times during

the year to newly hired or promoted employees, and in other special circumstances.

In fiscal 2025, we did not grant any stock options,

stock appreciation rights, or similar option-like instruments.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table sets forth information regarding the beneficial ownership of our common stock as of June 18, 2024, by each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock, each of our executive officers and directors, and all our officers and directors as a group.

Beneficial ownership is determined in accordance with the rules of the SEC and does not necessarily indicate beneficial ownership for any other purpose.

Under these rules, beneficial ownership includes those shares of common stock over which the stockholder has sole or shared voting or investment power.

It also includes shares of common stock that the stockholder has a right to acquire within 60 days through the exercise of any option or other right.

The percentage ownership of the outstanding common stock, which is based upon shares of common stock outstanding as of June 18, 2024, is based on the assumption, expressly required by the rules of the SEC, that only the person or entity whose ownership is being reported has exercised options to purchase shares of our common stock.

Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all shares of common stock beneficially owned by them.

Unless otherwise noted, the nature of the ownership set forth in the table below is the common stock of the Company.

The table below sets forth as of June 18, 2024, except as noted in the footnotes to the table, certain information with respect to the beneficial ownership of the Company’s common stock by (i) all persons or groups, according to the most recent Schedule 13D or Schedule 13G filed with the SEC or otherwise known to us, to be the beneficial owners of more than 5% of the outstanding common stock of the Company, (ii) each director of the Company, (iii) the executive officers named in the Summary Compensation Table, and (iv) all such executive officers and directors of the Company as a group.

(in thousands)

following table sets forth information regarding the beneficial ownership of our common stock as of June 20, 2025, by each person known

by us to be the beneficial owner of more than 5% of our outstanding shares of common stock, each of our executive officers and directors,

and all our officers and directors as a group.

ownership is determined in accordance with the rules of the SEC and does not necessarily indicate beneficial ownership for any other

Under these rules, beneficial ownership includes those shares of common stock over which the stockholder has sole or shared

voting or investment power.

It also includes shares of common stock that the stockholder has a right to acquire within 60 days through

the exercise of any option or other right.

The percentage ownership of the outstanding common stock, which is based upon shares of common

stock outstanding as of June 20, 2025, is based on the assumption, expressly required by the rules of the SEC, that only the person or

entity whose ownership is being reported has exercised options to purchase shares of our common stock.

otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all shares

of common stock beneficially owned by them.

Unless otherwise noted, the nature of the ownership set forth in the table below is the common

stock of the Company.

The table below sets forth as of June 20, 2025, except as noted in the footnotes to the table, certain information

with respect to the beneficial ownership of the Company’s common stock by (i) all persons or groups, according to the most recent

Schedule 13D or Schedule 13G filed with the SEC or otherwise known to us, to be the beneficial owners of more than 5% of the outstanding

common stock of the Company, (ii) each director of the Company, (iii) the executive officers named in the Summary Compensation Table,

and (iv) all such executive officers and directors of the Company as a group.

Shares Owned (in thousands)

Name and Address of Beneficial Owners/Named Executive Officers and Directors:

Number of Shares

Beneficially Owned

Ram Mukunda (2)

3 unchanged sentences

All Executive Officers and Directors as a group (5 persons)

*Based on 75,636,419 shares of common stock outstanding as of June 18, 2024.

Unless otherwise indicated, the address of each of the individuals listed in the table is c/o IGC Pharma, Inc., 10224 Falls Road, Potomac, MD 20854.

The beneficial ownership table does not include 810,752 shares of common stock that are owned by Mr.

83,891,586 shares of common stock outstanding as of June 20, 2025.

otherwise indicated, the address of each of the individuals listed in the table is c/o IGC Pharma, Inc., 10224 Falls Road, Potomac, MD

beneficial ownership table does not include 810,752 shares of common stock that are owned by Mr.

Mukunda’s spouse for which Mr.

Mukunda has no voting or financial rights.

The individual who holds voting and investment power in the investment manager is Mr.

individual who holds voting and investment power in the investment manager is Mr.

Loo See Yuen, the Director of Bradbury Asset Management.

1 unchanged sentence

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

During the last two fiscal years, we have not entered into any material transactions or series of transactions that would be considered material in which any officer, director, or beneficial owner of 5% or more of any class of our capital stock, or any immediate family member of any of the preceding persons, had direct or indirect material interest, nor are there any such transactions presently proposed, other than the agreements with the affiliates of our CEO as described under “Executive Compensation – Compensation for Executive Officers of the Company.”

Review, approval, or ratification of related party transactions

We have a written policy for the review and approval of transactions with related persons.

It is our policy for the disinterested members of our Board to review all related party transactions on a case-by-case basis.

To receive approval, a related-party transaction must have a business purpose for us and be on terms that are fair and reasonable to us and as favorable to us as would be available from non-related entities in comparable transactions.

Transaction with Related Parties

On March 22, 2024, the Company entered into the SPA with Bradbury Strategic Investment Fund A, resulting in approximately $3 million in gross proceeds.

than as described below, during the last two fiscal years, we have not entered into any material transactions or series of transactions

that would be considered material in which any officer, director, or beneficial owner of 5% or more of any class of our capital stock,

or any immediate family member of any of the preceding persons, had direct or indirect material interest, nor are there any such transactions

presently proposed, other than the agreements with the affiliates of our CEO as described under “Executive Compensation –

Compensation for Executive Officers of the Company.”

approval, or ratification of related party transactions

have a written policy for the review and approval of transactions with related persons.

It is our policy for the disinterested members

of our Board to review all related party transactions on a case-by-case basis.

To receive approval, a related-party transaction must

have a business purpose for us and be on terms that are fair and reasonable to us and as favorable to us as would be available from non-related

entities in comparable transactions.

with Related Parties

March 22, 2024, the Company entered into the SPA with Bradbury Strategic Investment Fund A, resulting in approximately $3 million in

gross proceeds.

The completion of the private placement is subject to customary closing conditions, including approval by the NYSE.

Under the terms of the private placement, IGC will issue approximately 8.8 million shares of unregistered common stock at a price of $0.34 per share.

the terms of the private placement, IGC will issue approximately 8.8 million shares of unregistered common stock at a price of $0.34

were no related party transactions in Fiscal 2025 and through the date of this Form 10-K.

PRINCIPAL ACCOUNTANT FEES AND SERVICES

Manohar Chowdhry & Associates (MCA) is our Principal Independent Registered Public Accounting Firm engaged to examine our financial statements for Fiscal 2024.

During the Company’s two most recent fiscal years ended March 31, 2024, and 2023, and through July 6, 2023, the Company did not consult with MCA on (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that may be rendered on the Company’s financial statements, and MCA has not provided either a written report or oral advice to the Company that was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue;

or (ii) the subject of any disagreement, as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions, or a reportable event within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.

Audit related and other fees

The table below shows the fees that we paid or accrued for the audit and other services provided by Manohar Chowdhry & Associates for Fiscal 2024 and Fiscal 2023.

This category includes the audit of our annual financial statements, review of financial statements included in our annual and quarterly reports and services that are normally provided by the independent registered public accounting firms in connection with engagements for those fiscal years.

This category also includes advice on audit and accounting matters that arose during, or as a result of, the audit or the review of interim financial statements.

Internal control audit fees

This category includes the audit of the Company’s internal control over financial reporting based on criteria established in Internal Control—Integrated Framework:

Chowdhry & Associates (MCA) is our Principal Independent Registered Public Accounting Firm engaged to examine our financial statements

for Fiscal 2025.

During the Company’s two most recent fiscal years ended March 31, 2025, and 2024, and through July 6, 2023, the

Company did not consult with MCA on (i) the application of accounting principles to a specified transaction, either completed or proposed,

or the type of audit opinion that may be rendered on the Company’s financial statements, and MCA has not provided either a written

report or oral advice to the Company that was an important factor considered by the Company in reaching a decision as to any accounting,

auditing, or financial reporting issue;

or (ii) the subject of any disagreement, as defined in Item 304(a)(1)(iv) of Regulation S-K and

the related instructions, or a reportable event within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.

related and other fees

table below shows the fees that we paid or accrued for the audit and other services provided by Manohar Chowdhry & Associates for

Fiscal 2025 and Fiscal 2024.

category includes the audit of our annual financial statements, review of financial statements included in our annual and quarterly reports

and services that are normally provided by the independent registered public accounting firms in connection with engagements for those

fiscal years.

This category also includes advice on audit and accounting matters that arose during, or as a result of, the audit or the

review of interim financial statements.

control audit fees

category includes the audit of the Company’s internal control over financial reporting based on criteria established in Internal

Control—Integrated Framework:

(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Audit-related fees

This category consists of assurance and related services by the independent registered public accounting firms that are reasonably related to the performance of the audit or review of our financial statements and are not reported above under “Audit Fees.” The services for the fees disclosed under this category include services relating to our registration statement and consultation regarding our correspondence with the SEC.

This category consists of professional services rendered for tax compliance, tax planning, and tax advice.

These services include tax return preparation and advice on state and local tax issues.

All other fees

This category consists of fees for other miscellaneous items.

Audit-related

category consists of assurance and related services by the independent registered public accounting firms that are reasonably related

to the performance of the audit or review of our financial statements and are not reported above under “Audit Fees.” The

services for the fees disclosed under this category include services relating to our registration statement and consultation regarding

our correspondence with the SEC.

category consists of professional services rendered for tax compliance, tax planning, and tax advice.

These services include tax return

preparation and advice on state and local tax issues.

category consists of fees for other miscellaneous items.

(in thousands)

2 unchanged sentences

All other fees

Policy on pre-approval of audit and permissible non-audit services of independent auditors

Consistent with SEC policies regarding auditor independence, the audit committee of our Board of Directors has responsibility for appointing, setting compensation, and overseeing the work of the independent auditor.

In recognition of this responsibility, our Board of Directors has established a policy to pre-approve all audit and permissible non-audit services provided by the independent auditor.

Prior to the engagement of the independent auditor for the next year’s audit, management may submit, if necessary, an aggregate of services expected to be rendered during that year for each of the following four categories of services to our Board of Directors for approval.

Audit services include audit work performed in the preparation of financial statements and audit of internal controls, as well as work that generally only the independent auditor can reasonably be expected to provide, including comfort letters, statutory audits, and attest services and consultation regarding financial accounting and/or reporting standards.

Audit-Related services are for assurance and related services that are traditionally performed by the independent auditor, including due diligence related to mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements.

Tax services include all services performed by the independent auditor’s tax personnel except those services specifically related to the audit of the financial statements and includes fees in the areas of tax compliance, tax planning, and tax advice.

Other Fees are those associated with services not captured in the other categories.

Prior to engagement, our Board of Directors pre-approves these services by category of service.

The fees are budgeted, and our Board of Directors requires the independent auditor and management to report actual fees versus the budget periodically throughout the year by category of service.

During the year, circumstances may arise when it may become necessary to engage the independent auditor for additional services not contemplated in the original pre-approval.

In those instances, our Board of Directors requires specific pre-approval before engaging the independent auditor.

Our audit committee may delegate pre-approval authority to one or more of its members.

The member to whom such authority is delegated must report, for informational purposes only, any pre-approval decisions to our Board of Directors at its next scheduled meeting.

Pre-approved services

The Audit Committee’s charter provides for pre-approval of audit, audit-related and tax services to be performed by the independent auditors.

The Audit Committee approved the audit, audit-related and tax services to be performed by independent auditors and tax professionals in Fiscal 2024.

The charter also authorizes the Audit Committee to delegate to one or more of its members pre-approval authority with respect to permitted services.

The decisions of any Audit Committee member to whom pre-approval authority is delegated must be presented to the full Audit Committee at its next scheduled meeting.

on pre-approval of audit and permissible non-audit services of independent auditors

with SEC policies regarding auditor independence, the audit committee of our Board of Directors has responsibility for appointing, setting

compensation, and overseeing the work of the independent auditor.

In recognition of this responsibility, our Board of Directors has established

a policy to pre-approve all audit and permissible non-audit services provided by the independent auditor.

Prior to the engagement of

the independent auditor for the next year’s audit, management may submit, if necessary, an aggregate of services expected to be

rendered during that year for each of the following four categories of services to our Board of Directors for approval.

Audit services

include audit work performed in the preparation of financial statements and audit of internal controls, as well as work that generally

only the independent auditor can reasonably be expected to provide, including comfort letters, statutory audits, and attest services

and consultation regarding financial accounting and/or reporting standards.

Audit-Related services

are for assurance and related services that are traditionally performed by the independent auditor, including due diligence related to

mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements.

include all services performed by the independent auditor’s tax personnel except those services specifically related to the audit

of the financial statements and includes fees in the areas of tax compliance, tax planning, and tax advice.

are those associated with services not captured in the other categories.

to engagement, our Board of Directors pre-approves these services by category of service.

The fees are budgeted, and our Board of Directors

requires the independent auditor and management to report actual fees versus the budget periodically throughout the year by category

During the year, circumstances may arise when it may become necessary to engage the independent auditor for additional services

not contemplated in the original pre-approval.

In those instances, our Board of Directors requires specific pre-approval before engaging

the independent auditor.

audit committee may delegate pre-approval authority to one or more of its members.

The member to whom such authority is delegated must

report, for informational purposes only, any pre-approval decisions to our Board of Directors at its next scheduled meeting.

Audit Committee’s charter provides for pre-approval of audit, audit-related and tax services to be performed by the independent

The Audit Committee approved the audit, audit-related and tax services to be performed by independent auditors and tax professionals

in Fiscal 2025.

The charter also authorizes the Audit Committee to delegate to one or more of its members pre-approval authority with

respect to permitted services.

The decisions of any Audit Committee member to whom pre-approval authority is delegated must be presented

to the full Audit Committee at its next scheduled meeting.

The Audit Committee has not delegated such authority to its members.

Audit committee report

The Audit Committee of the Board is composed of two directors, each of whom meets the current NYSE American test for independence.

The Committee acts under a written charter adopted by the Board.

The Audit Committee has prepared the following report on its activities with respect to the Company’s audited financial statements for Fiscal 2024 (the Audited Financial Statements):

The Audit Committee reviewed and discussed the Company’s Audited Financial Statements with management;

The Audit Committee discussed with Manohar Chowdhry & Associates, the Company’s independent auditors for Fiscal 2024, the matters required to be discussed by AS 1300, as adopted by the Public Company Accounting Oversight Board;

The Audit Committee received from the independent auditors the written disclosures regarding auditor independence and the letter required by Independence Standards Board Standard No.

1 (Independence Discussions with Audit Committees), discussed with Manohar Chowdhry & Associates, its independence from the Company and its management, and considered whether Manohar Chowdhry & Associates’ provision of non-audit services to the Company was compatible with the auditor’s independence;

Based on the review and discussion referred to above, and in reliance thereon, the Audit Committee recommended to the Board that the Audited Financial Statements be included in the Company’s Annual Report on Form 10-K for Fiscal 2024, for filing with the U.S.

Securities and Exchange Commission.

All members of the Audit Committee concur in this report.

AUDIT COMMITTEE:

Richard Prins

committee report

Audit Committee of the Board is composed of two directors, each of whom meets the current NYSE American test for independence.

The Committee

acts under a written charter adopted by the Board.

The Audit Committee has prepared the following report on its activities with respect

to the Company’s audited financial statements for Fiscal 2025 (the Audited Financial Statements):

Audit Committee reviewed and discussed the Company’s Audited Financial Statements with management;

Audit Committee discussed with Manohar Chowdhry & Associates, the Company’s independent auditors for Fiscal 2025, the matters

required to be discussed by AS 1300, as adopted by the Public Company Accounting Oversight Board;

Audit Committee received from the independent auditors the written disclosures regarding auditor independence and the letter required

by Independence Standards Board Standard No.

1 (Independence Discussions with Audit Committees), discussed with Manohar Chowdhry &

Associates, its independence from the Company and its management, and considered whether Manohar Chowdhry & Associates’ provision

of non-audit services to the Company was compatible with the auditor’s independence;

on the review and discussion referred to above, and in reliance thereon, the Audit Committee recommended to the Board that the Audited

Financial Statements be included in the Company’s Annual Report on Form 10-K for Fiscal 2025, for filing with the U.S.

and Exchange Commission.

members of the Audit Committee concur in this report.

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

The exhibits listed in the accompanying index to exhibits are filed, furnished, or incorporated by reference as part of this Annual Report on Form 10-K.

The exhibits listed in the accompanying index

to exhibits are filed, furnished, or incorporated by reference as part of this Annual Report on Form 10-K.

(a) All Financial Statements

Index to Consolidated Financial Statements

Report of Independent Registered Public Accounting Firms

Consolidated Balance Sheets

Consolidated Statements of Operations and Comprehensive Loss

Consolidated Statements of Stockholders’ Equity

Consolidated Statements of Cash Flows

Notes to Consolidated Financial Statements

(b) Exhibits required by Item 601 of Regulation S-K

to Consolidated Financial Statements

of Independent Registered Public Accounting Firms

Balance Sheets

Statements of Operations and Comprehensive Loss

Statements of Stockholders’ Equity

Statements of Cash Flows

to Consolidated Financial Statements

(b) Exhibits required by Item 601 of Regulation

Amended and Restated Articles of Incorporation of the Registrant, as amended on August 1, 2012.

20 unchanged sentences

and O-Bank, CO., LTD (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 7, 2023).

Extension of Master Loan Agreement between IGC Pharma, Inc.

and O-Bank, CO., LTD.

(incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 2, 2024).

Form of Share Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 7, 2023).

2 unchanged sentences

IGC Form of Board of Directors Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 13, 2024).

Share Purchase Agreement, dated September 25, 2024, between IGC Pharma, Inc.

and Moran Global Strategies, Inc.

(incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 27, 2024).

Insider Trading Policy

Subsidiaries of India Globalization Capital, Inc.

4 unchanged sentences

Certificate pursuant to 18 USC.

Dodd-Frank Clawback Policy

Inline XBRL Instance Document.

Inline XBRL Taxonomy Extension Schema Document.

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

Inline XBRL Taxonomy Extension Definition Linkbase Document.

Inline XBRL Taxonomy Extension Label Linkbase Document.

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101).

Dodd-Frank Clawback Policy (incorporated by reference to Exhibit 97.1 to the Company’s Annual Report on Form 10-K filed on June 24, 2024)

Clinical Study Presentation, dated June 17, 2025 (incorporated by reference to Exhibit 99.1 to the Company’s Registration Statement on Form 8-K filed on June 17, 2025).

XBRL Instance Document.

XBRL Taxonomy Extension Schema Document.

XBRL Taxonomy Extension Calculation Linkbase Document.

XBRL Taxonomy Extension Definition Linkbase Document.

XBRL Taxonomy Extension Label Linkbase Document.

XBRL Taxonomy Extension Presentation Linkbase Document.

Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101).

Filed herewith.

3 unchanged sentences

FORM 10 - K SUMMARY

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Pursuant to the requirements of Section 13 or

15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,

thereunto duly authorized.

IGC PHARMA, INC.

8 unchanged sentences

(Principal Financial Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Pursuant to the requirements of the Securities

Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and

on the dates indicated.

June 27, 2025

18 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 9A. Controls and Procedures